Beijing Biostar Pharmaceuticals

2563 · HKEX

Public Market Listing

2563HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Beijing Biostar Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Tubulin / microtubulesSmall molecule
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
UtidelonePhase 2Non-small Cell Lung Cancer Patients with Brain Metastases
Est. primary completion 2026-12-01 · NCT06683703 · CT.gov ↗
What to watch
UtidelonePhase 2Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer, Bile Duct Cancer
Est. primary completion 2026-12-31 · NCT06730581 · CT.gov ↗
What to watch
2027 (2)
January 2027 (1)
UtidelonePhase 2HER2-negative Breast Cancer Patients With Brain Metastases
Est. primary completion 2027-01-15 · NCT06764940 · CT.gov ↗
What to watch
March 2027 (1)
UtidelonePhase 2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Est. primary completion 2027-03 · NCT07044349 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
UtidelonePhase 3Advanced Breast Cancer
Est. primary completion 2028-03-01 · NCT07684456 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
UtidelonePhase 2/3Gastric or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2030-09-01 · NCT06841679 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1———$7.5Mreport ↗